PARP inhibitors take center stage at the Society of Gynecologic Oncology’s 25th Annual Winter Meeting
The FDA accepted a supplemental new drug application for niraparib, treating women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status, based on data from the PRIMA study.
A new tool, in combination with those already existing, could distinguish between patients with malignant and benign ovarian masses, as well as those with a benign ovarian mass and normal ovaries.
The O-RADS MRI tool could potentially reduce unnecessary or over-extensive surgery in patients with various types of ovarian cancer.
This large meta-analysis was found to support the GCIG Fifth Ovarian Cancer Consensus statement that OS is the preferred primary end point.
A recent study suggested the activation of apelin/APJ signaling decreased efficacy in VEGF treatment, while bevacizumab decreased disease-free survival rates with increased expression of apelin in patients of ovarian cancer.
The priority review was based on results from the phase III PAOLA-1 trial comparing the addition of olaparib to bevacizumab vs the standard-of-care alone.
Largest analysis of data to date shows no link between use of talc powder and rate of ovarian cancer incidence
A study showed that first-line treatment for epithelial ovarian cancer using weekly dose-dense chemotherapy did not improve progression-free survival, compared with 3-weekly chemotherapy, in European women.
Patients recently diagnosed with ovarian cancer indicated that they would accept a moderately higher risk of complication and surgical mortality in exchange for higher overall survival.